How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Synergo for non-muscle-invasive bladder cancer

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Synergo shows promise for high-risk non-muscle-invasive bladder cancer that has not responded to or has recurred after BCG treatment, or when people cannot or do not want to have BCG treatment. However there is not enough good-quality evidence to support the case for routine adoption.

1.2 Research is recommended on the benefits and costs of Synergo for high-risk non-muscle-invasive bladder cancer. This should include:

  • collecting and analysing local audit data on how Synergo is used in the NHS

  • assessing the relative benefits and cost of Synergo compared with other device-assisted chemotherapy technologies or standard care.

Find out details of required outcomes in further research.

Why the committee made these recommendations

Synergo delivers chemotherapy and microwave energy to the bladder. Clinical experts advise that chemotherapy using Synergo would be used in the NHS for high-risk non-muscle-invasive bladder cancer after BCG has not worked, or if someone cannot or does not want to have BCG.

Synergo offers an alternative treatment to the limited options available for these people, which include radical cystectomy (removal of the bladder) or regular cystoscopies (a procedure to look inside the bladder to check for tumours and remove them if necessary). The experts advise that using Synergo for intermediate-risk cancer is unlikely to be practical. Also, there are other effective treatments available for these people.

There is some evidence that chemotherapy using Synergo could reduce the chance of the cancer returning. But it's from a trial that does not reflect how Synergo is likely to be used in the NHS, that is, in people with high-risk cancer after BCG has not worked or when people cannot or do not want to have BCG treatment.

Cost modelling for Synergo is uncertain and does not reflect how it is likely to be used in the NHS. Because of this and the limitations in the clinical evidence, further research is recommended into using Synergo in high-risk non-muscle-invasive bladder cancer.